Istari Oncology, Inc., is a clinical-stage biotechnology company developing innovative immunotherapies for the treatment of patients with solid tumors. Istari has built a passionate and experienced leadership team focused on clinical trial strategy and driving execution while seeking opportunities for partnership and collaboration with the world’s leading cancer centers and oncology biotech firms.
Our principal asset is lerapolturev, an investigational immunotherapy based on the Sabin oral poliovirus vaccine, genetically engineered to eliminate neurotoxicity and leverage multiple unique mechanisms of action to activate a systemic antitumor response to fight cancer.
At Istari, we are pioneering a new field of immunotherapies to give hope to patients in their fight against cancer. Our relationships with cancer patients, survivors, and their caregivers are personal and profound. By combining a data-driven mindset with our desire to change the outcomes in favor of patients, we are determined to improve the lives of others. Our mission moves us to unite our talents to work with purpose to win the fight against cancer.
We value team-focused collaboration and a willingness to take on any task, no matter how small. Scientific debate, data, and compassion drive our decisions.
And at the end of the day, we celebrate all we’ve accomplished with a healthy dose of fun, because we take our work—not ourselves—seriously.